Pipeline· July 2, 2026 · 17 min read
The Anti-Obesity Phase 3 Pipeline: Active Trials and Mechanisms
By Ran Chen#GLP-1#Weight Loss#Clinical Evidence
Topic
Clinical Evidence
Trial design, endpoints, real-world evidence, safety updates, and how evidence translates into market access.
Pipeline· July 1, 2026 · 19 min read
Centanafadine PDUFA July 24, 2026: Pipeline and Access for Otsuka's NDSRI
By Ran Chen#PDUFA Date#Priority Review#CNS and Migraine
Pricing & Access· June 28, 2026 · 21 min read
Casgevy Access Guide: CMS CGT Model, State Medicaid Criteria, and the ATC Network
By Ran Chen#Medicaid#Prior Authorization#Gene Therapy
Biosimilars· June 23, 2026 · 18 min read
Keytruda Biosimilar Tracker: The 7-Developer Race to the 2028 Cliff
By Ran Chen#Biosimilars#Oncology#FDA Approval
Evidence· June 21, 2026 · 9 min read
CGRP inhibitors in FAERS: 120,759 adverse-event reports by the numbers
Evidence· June 19, 2026 · 13 min read
IL-17 and IL-23 biologics in FAERS: 400,283 adverse-event reports by the numbers
Evidence· June 19, 2026 · 14 min read
Insulins in FAERS: 454,039 adverse-event reports by the numbers
Evidence· June 19, 2026 · 14 min read
TNF inhibitors in FAERS: 1,561,353 adverse-event reports by the numbers
Policy· June 14, 2026 · 13 min read
How to read an FDA FAERS report: what spontaneous reporting can and cannot prove
Evidence· June 14, 2026 · 14 min read